Retinal vein occlusion in patients under 50 years. Analysis of vascular risk factors, thrombophilia, carotid ultrasound findings and uncommon aetiologies

González, I. Sanlés; Lecumberri, J.J. Napal; Pérez‐Montes, Rocío; Varona, A. Cerveró; Rojo, A.; Hernández, José L.

doi:10.1016/j.oftale.2021.12.002

Cited by 2 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evidence has confirmed that CP is observed in 54.3% and 76.7% of patients with RVO and branch RVO, respectively [ 3 , 4 ]. Retinal arteriosclerosis and thrombosis caused by CP can result in retinal venous reflux disorders and secondary RVO [ 3 – 5 ]. RVO can be a predictor of CP and should be evaluated using carotid Doppler ultrasound [ 1 ].…”

Section: Introductionmentioning

confidence: 99%

Clinical effects of atorvastatin combined with conbercept in the treatment of patients with macular edema secondary to retinal vein occlusion and carotid plaque: study protocol for a prospective randomized controlled trial

Yao,

Wang,

Yang

et al. 2024

Trials

View full text Add to dashboard Cite

Introduction Intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) drugs have been widely used in patients with macular edema (ME) secondary to retinal vein occlusion (RVO); however, recurrence is a major concern. This study aims to observe the clinical effects of atorvastatin and intravitreal therapy in the treatment of patients with branch or central RVO-ME and coexistent carotid plaques (CP). Methods and analysis A prospective randomized controlled clinical trial will be conducted. Sixty-four patients diagnosed with branch or central RVO-ME and coexistent CP will be enrolled and randomly allocated in a 1:1 ratio to the control and experimental groups. The control group will be treated with intravitreal conbercept monthly for 3 months, followed by monthly evaluation and injection of pro re nata (PRN) for 12 months, while the experimental group will be treated with oral atorvastatin 20 mg daily combined with the control group treatment. If a drop of best-corrected visual acuity (BCVA) is more than five Early Treatment Diabetic Retinopathy Study (ETDRS) letters (one line) or an increment in central subfield thickness (CSFT) of 100 μm (or a 10% increment from the previous visit), intravitreal re-treatment will be performed. Outcome measurements include CSFT, BCVA, number of injections, and incidence of adverse events during the 12-month follow-up period. Differences between groups will be evaluated using Student’s t-test, and comparisons between groups will be evaluated using repeated-measures analysis of variance. Ethics and dissemination The study has been approved by the Institutional Review Board of Nanjing Lishui People’s Hospital, Nanjing, China (approval number 2023KY0418-12, dated 18 April 2023), and has been registered on chictr.org.cn. Written informed consent will be collected from each patient and the results of this trial will be submitted to a peer-reviewed journal. Trial registration Chinese Clinical Trial Registry ChiCTR2300071359. Registered on 12 May 2023.

show abstract

Section: Introductionmentioning

confidence: 99%